Neutralizing Antibodies against Autologous Human Immunodeficiency Virus Type 1 Isolates in Patients with Increasing CD4 Cell Counts despite Incomplete Virus Suppression during Antiretroviral Treatment

LOREDANA SARMATI,1 GABRIELLA D’ETTORRE,2 EMANUELE NICASTRI,3 LUCIA ERCOLI,1 ILARIA UCCELLA,1 PAOLA MASSETTI,2 SAVERIO GIUSEPPE PARISI,4 VINCENZO VULLO,2 AND MASSIMO ANDREONI1*  

Department of Public Health, University “Tor Vergata,”1 Department of Infectious and Tropical Diseases, University of Rome “La Sapienza,”2 and National Institute of Infectious Diseases, IRCCS L. Spallanzani,3 Rome, and Institute of Immunology and Infectious Diseases, University of Verona, Verona,4 Italy

Received 19 December 2000/Returned for modification 8 February 2001/Accepted 18 April 2001

Antiretroviral-treated human immunodeficiency virus (HIV) type 1-seropositive individuals can remain clinically stable for a long period of time with an increasing CD4 cell count irrespective of incomplete viral suppression. We evaluated the role of neutralizing antibody (NtAb) activity in the etiopathogenesis of this viro-immunological disconnection (defined as an increasing CD4⁺-cell count despite a persistent, detectable viral load during antiretroviral therapy) in 33 patients failing therapy with two analogue nucleoside reverse transcriptase inhibitors. An HIV NtAb titer of ≥1:25 was detected in specimens from 16 out of 33 (48%) patients. A significant correlation was found between NtAb titers and CD4⁺-cell counts (P = 0.001; r = 0.546) but not with HIV RNA levels in plasma. Five patients with a viro-immunological disconnection had an NtAb titer of >1:125, statistically higher than the NtAb titers for the remaining 28 patients with both virologic and immunologic failure (P < 0.0001). The HIV-specific humoral immune response could play a role during antiretroviral treatment to improve immunological function despite an incomplete suppression of viral load.

Human immunodeficiency virus type 1 (HIV-1)-seropositive individuals failing antiretroviral treatment can remain clinically stable for a long period of time (7), showing an increasing CD4 cell count irrespective of incomplete viral suppression (6, 8). The clinical implications of such a viro-immunological disconnection (defined as an increasing CD4⁺-cell count despite a persistent, detectable viral load during antiretroviral treatment) remain uncertain. Different factors, including decreased viral fitness (10), direct effect of protease inhibitors on immune response (1, 13), and effective humoral and cell-mediated immunological activity (2, 15), have been directly related to the lack of HIV disease progression.

Neutralizing antibody (NtAb) activity has been detected in HIV primary infection simultaneously with a decrease of viral load (14) in long-term nonprogressor patients (4) and during antiretroviral therapy in the chronic phase of HIV infection (3, 13), suggesting an active role of this factor in viral clearance. Conversely, the NtAb response is minimal or absent in patients who progress rapidly to AIDS and death (5).

The aim of the present study was to evaluate the NtAb activity against contemporaneous autologous HIV-1 isolates in 33 HIV-infected adult patients failing antiretroviral treatment and to determine the role of NtAb in the etiopathogenesis of the viro-immunological disconnection.

Thirty-three consecutive patients (21 males and 12 females), all failing treatment with a combination of two nucleoside analogues (zidovudine plus lamivudine), were enrolled in this cross-sectional study.

Plasma HIV-1 RNA levels were measured by using an AmpliC B A virus isolated at the time of serum collection was determined by microculture neutralization assay as previously described (13). Sera from two seronegative subjects were used as negative controls. The neutralizing titer was calculated by interpolation (according to the method of Reed and Muench) as the reciprocal of the dilution that reduced the number of infected cultures by 50%.

The levels of RANTES (regulated upon activation, normal T-cell expressed and secreted) and MIP-1α and -1β (macrophage inflammatory protein-1α and 1β) in plasma were measured by a quantitative enzyme-linked immunosorbent assay (Quantikine; R&D Systems, Minneapolis, Minn.).

Data were analyzed by the Mann-Whitney U test, χ² test, and linear correlation test.

The correlation between NtAb titer and immunological and virological characteristics of patients is reported in Table 1. An HIV NtAb titer of ≥1:25 was detected in 16 out of 33 (48%) patients; high levels of NtAb (>1:125) were present in 6 (18%) patients. A significant correlation was found between NtAb
titers and CD4\(^+\)-cell counts (P = 0.001; r = 0.546) and the number of days required to isolate HIV strains from plasma (P = 0.026; r = 0.367) (data not shown). No significant correlation was found between HIV RNA copy number and NtAb titer (P = −0.25; r = 0.17). However, the patients with the highest NtAb titers (>1:125) had the lowest viral load.

Twenty-one out of 27 patients (77%) with NtAb titers of <1:125 had an SI viral strain, while 4 out of 6 patients (66%) with an NtAb titer of >1:125 showed an NSI isolate. No difference with regard to β-chemokine levels in plasma was found between patients with or without NtAb activity. None of the 33 patients appeared to be homozygous (Δ32/Δ32) or heterozygous (WT/Δ32) for the partial deletion of the CCR-5 allele (data not shown).

Table 2 shows the virological and immunological parameters of antiretroviral-treated patients according to the presence of viro-immunological disconnection, defined as an increase of >100 CD4\(^+\) cells with respect to the pretreatment value despite a persistent, detectable viral load (>4 log\(_{10}\)). Five patients with viro-immunological disconnection had an NtAb titer of >1:125, statistically higher than the NtAb titers for the remaining 28 patients with both virologic and immunologic failure (P < 0.0001). Particularly, in this last group, NtAb titers for 17 individuals were below the limit of detection of the assay, titers for 10 individuals were intermediate (1:25 to 1:125), and only one individual had a high NtAb titer (1:933).

Determination of β-chemokine levels in plasma showed similar results in two groups, although patients with viro-immunological disconnection showed the highest production of RANTES (data not shown). No statistical difference was detected with regard to the HIV-1 viral loads of the two groups, while a significantly higher CD4\(^+\)-cell count, with a mean increase of 118 lymphocytes with respect to the pretreatment level, was found in patients with viro-immunological disconnection. Moreover, a retrospective analysis of pretherapy CD4\(^+\)-cell counts showed a level of >200 CD4\(^+\) cell/\(\mu\)m\(^3\) in all but one patient with viro-immunological disconnection and in 3 out of 28 patients with virological and immunological failure.

The presence of NtAb activity against autologous HIV-1 primary isolates was detected in viremic patients treated with a double-nucleoside antiretroviral regimen during the chronic phase of HIV infection. The HIV-specific humoral immune response could play an important role in controlling HIV disease progression. NtAb may provide protection by blocking HIV infection and limiting the widespread of cell virus (4), thus moderating the concentration of infectious cells and slowing the rate of CD4\(^+\)-cell depletion (9). In this study, in patients with virological failure during antiretroviral treatment, a significant correlation between NtAb titers and CD4\(^+\)-cell counts was found. Particularly, the presence of a significant NtAb titer against autologous virus was detected in patients with a CD4\(^+\)-cell count of >200 cells/\(\mu\)m\(^3\) before starting therapy and an increase of CD4\(^+\)-cell count during antiretroviral treatment.

Patients treated at an earlier stage of chronic HIV-1 infection have a higher humoral immune response than individuals with pretreatment CD4 cell counts of <200 cells/\(\mu\)m\(^3\) (2, 3). However, other factors, including decreased viral fitness, adherence to treatment, immunological effects of drugs, resistance to antiretroviral drugs, and HIV-specific cellular immune response, can play a role in viro-immunological disconnection during antiretroviral treatment.

The lack of an evident association between NtAb titer and viral load in this study agrees with previous reports (4, 12) and casts doubts on the ability of NtAb activity to suppress completely the replication of the contemporaneous autologous virus in vivo. On the other hand, the evidence of lower viremia

---

**TABLE 1. Characteristics of patients according to NtAb activity against contemporaneous autologous HIV-1 isolate**

| Parameter                             | Value for NtAb titer | P     |
|---------------------------------------|----------------------|-------|
|                                       | <1:25                | 1:25–1:125 | >1:125 |
| Number of patients                    | 17                   | 10     | 6     |
| Median no. of CD4\(^+\) cells/\(\mu\)l (range) | 21 (2–220)           | 40 (3–101) | 305 (23–440) | 0.001 |
| Median log HIV RNA copies/ml (range)  | 5.65 (4.52–6.38)     | 5.28 (4.45–5.9) | 5.03 (4.18–5.36) | 0.25 |
| Median NtAb titer (range)             | 1:631 (1:281–1:1,413) | <1:25 (1:25–1:933) | <0.0001 |
| No. with SI phenotype/no. with NSI phenotype | 11/6                 | 10/0   | 2/4   |
| Mean level of MIP-1α in plasma ± SD (pg/ml) | 1,826 ± 1,765        | 2,178 ± 2,345 | 2,048 ± 1,944 | NS* |
| Mean level of MIP-1β in plasma ± SD (pg/ml) | 1,267 ± 1,363        | 1,088 ± 1,063 | 1,160 ± 1,099 | NS |
| Mean level of RANTES in plasma ± SD (pg/ml) | 10,708 ± 10,344      | 10,309 ± 11,050 | 11,500 ± 11,844 | NS |

---

**TABLE 2. Virological and immunological parameters of patients according to viro-immunological disconnection**

| Parameter                             | Value for patients with virological failure and: Immunological disconnection | Immunological concordance | P     |
|---------------------------------------|-----------------------------------------------------------------------------|---------------------------|-------|
| Number of patients                    | 5                                                                           | 28                        |       |
| Median NtAb titer (range)             | 1:631 (1:281–1:1,413)                                                       | <1:25 (1:25–1:933)       | <0.0001 |
| Median no. of CD4\(^+\) cells/\(\mu\)l (range) | 207 (103–247)                                                               | 86 (4–245)               | 0.02  |
| Pretreatment                          | 325 (263–440)                                                               | 22 (2–220)               | <0.0001 |
| At enrollment                         | 5.04 (4.18–5.36)                                                            | 5.52 (4.45–6.38)         | 0.1   |
| Median duration of treatment\(^a\) (range) (days) | 1/4                                                                       | 22/6                     | 0.03  |
| No. with SI phenotype/no. with NSI phenotype | 369 (150–1,510)                                                             | 444 (171–1,329)          | 0.8   |

---

\(a\) Treatment with zidovudine plus lamivudine.
in patients with very advanced HIV infection and high NtAb titers (>1:125) could explain the role of NtAb in partial viral clearance, reduction of virus escape variants, and slower HIV disease progression (11). In this study, the production of β-chemokines does not seem to differ significantly between patients with different levels of NtAb activity.

In conclusion, the presence of significant titers of NtAb against autologous contemporaneous HIV-1 isolates in patients with sustained CD4 cell counts in spite of virologic failure has interesting clinical implications. A longitudinal, randomized clinical trial needs to be done to analyze whether this phenomenon is associated with a sustained clinical benefit and to evaluate the advantage of switching therapy in instances of virological and immunological disconnection.

REFERENCES
1. Andre, P., M. Groettrup, P. Klenerman, R. de Giuli, B. L. Booth, Jr., V. Cerundolo, M. Bonneville, E. Jotereau, R. M. Zinkernagel, and V. Lotteau. 1998. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc. Natl. Acad. Sci. USA 95:13120–13124.
2. Autran, J. D., G. Carcelain, T. S. Li, C. Blanc, D. Mathez, R. Tubiana, C. Katlama, P. Debre, and J. Liebowitch. 1997. Positive effects of combined antiretroviral therapy on CD4$^+$ T cell homeostasis and function in advanced HIV disease. Science 277:112–116.
3. Binley, J. B., A. Trkola, T. Ketas, D. Schiller, B. Clas, S. Little, D. Richman, A. Hurley, M. Markowitz, and J. P. Moore. 2000. The effect of HAART on binding and neutralizing antibody response to human immunodeficiency virus type 1 infection. J. Infect. Dis. 182:945–949.
4. Carotenuto, P., D. Lossi, L. Kelderms, F. de Wolf, and J. Goudsmidt. 1998. Neutralizing antibodies are positively associated with CD4$^+$ T cell counts and T-cell function in long-term AIDS free infection. AIDS 12:1591–1600.
5. Clerici, M., C. Balotta, D. Trabattoni, L. Papagno, S. Ruzzante, S. Rusconi, M. L. Fusi, M. L. Colombo, and M. Galli. 1996. Chemokine production in HIV-seropositive long-term asymptomatic individuals. AIDS 10:1432–1433.
6. Kaufmann, D., G. Pantaleo, G. Philippe Sudre, and A. Telenti for the Swiss HIV Cohort Study. 1998. CD4-cell count in HIV-1-infected individuals remaining vireamic with HAART. Lancet 351:723–724.
7. Keet, I. P. M., A. Krol, M. Koot, M. Roos, F. de Wolf, F. Miedema, and R. A. C. Coutinho. 1994. Predictors of disease progression in HIV-infected homosexual men with CD4$^+$ cells <200 × 10$^3/l$ but free of AIDS-defining clinical disease. AIDS 8:1577–1583.
8. Liegler, T. J., M. S. Hayden, K. H. Lee, R. Hoh, S. G. Deeks, and R. M. Granta. 2001. Protease inhibitor-resistant HIV-1 from patients with preserved CD4 cell counts is cytopathic in activated CD4$^+$ lymphocytes. AIDS 15:179–184.
9. Lu, W., J. W. K. Shib, J. M. Tourani, D. Eme, H. J. Alter, and J. M. Andrieu. 1993. Lack of isolate-specific neutralizing activity is correlated with an increased viral burden in rapidly progressing HIV-1-infected patients. AIDS 7:S91–S99.
10. Martinez-Picado, J., A. Savara, L. Sutton, and R. T. D’Aquila. 1999. Repli
cative fitness of protease inhibitor resistant mutants of human immunodefi-
ciency virus type 1. J. Virol. 73:3744–3752.
11. Moore, J. P., and D. D. Ho. 1995. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS 9:S1–S19.
12. Pellegrin, L. E. Legrand, D. Neau, P. Bonot, B. Masquelier, J. L. Pellegrin, J. M. Ragnaud, N. Bernard, and H. J. Fleury. 1996. Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 in
fec
tion and relationship with plasma and cellular viral loads. J. Acquir. Immune Defic. Syndr. 11:438–447.
13. Sarmati, L., E. Nicastro, G. el-Sawaf, L. Ercoli, S. Vella, and M. Andreoni. 1997. Increase in neutralizing antibody titer against sequential autologous HIV-1 isolates after 16 weeks saquinavir treatment. J. Med. Virol. 53:313–318.
14. Tsang, M. L., L. A. Evans, P. McQueen, L. Hurren, C. Byrne, R. Penny, B. Tindall, and D. Cooper. 1994. Neutralizing antibodies against autologous human immunodeficiency virus type 1 isolates after seroconversion. J. Infect. Dis. 170:1141–1147.
15. Wilson, J. D., N. Imami, A. Watkins, J. Gill, P. Hay, B. Gazzard, M. Westby, and F. M. Gotch. 2000. Loss of CD4$^+$ T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to diseases. J. Infect. Dis. 182:792–798.